Agenus Inc. (AGEN)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-11) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-16) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-10) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-11) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-12) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-11) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 · 99.2 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-14) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Income (loss) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (deficit) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Accrued and Other Current Liabilities | ||
| Accrued Liabilities | — |
|
| Acquired Intangible Assets | — |
|
| Assets Held For Sale | ||
| Benefit Plans | — |
|
| Business Acquisitions | — |
|
| Business, Liquidity and Basis of Presentation | — |
|
| Cash Equivalents | — |
|
| Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Debt | ||
| Description of Business | — |
|
| Equity | ||
| Fair Value Measurements | ||
| Geographical Information | — |
|
| Goodwill and Acquired Intangible Assets | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Investment In Mink Therapeutics, Inc. | — |
|
| Investments | ||
| Leases | — |
|
| Liability Related To The Sale of Future Royalties and Milestones | ||
| License, Research and Other Agreements | — |
|
| Net Income (loss) Per Share | — |
|
| Net Loss Per Share | — |
|
| Non-controlling Interest | ||
| Pay Vs Performance Disclosure | — |
|
| Property, Plant and Equipment | — |
|
| Recent Accounting Pronouncements | — |
|
| Related Party Transactions | ||
| Restricted Cash | ||
| Revenue From Contracts With Customers | ||
| Sale of Manufacturing Facilities To Zydus | — |
|
| Segment and Geographic Information | — |
|
| Segment Information | — |
|
| Series C-1 Convertible Preferred Stock | — |
|
| Share-based Compensation Plans | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||